Section

300% rise in net profit in Q3; Analysts see exciting times ahead for this mid-cap firm

By Business Today - 9 months ago
This is despite a 140% jump in the pharmaceutical firm’s stock prices over the past year

Disclaimer : Mymoneytimes implements extreme caution and care in collecting data before publication. Mymoneytimes does not liable for the adequacy, accuracy or completeness of any given information. Hence we are not liable for any kind of direct or indirect loss caused by the use of such information.